Your English writing platform
Discover LudwigSuggestions(2)
Exact(43)
Furthermore, von Minckwitz and coworkers [ 49] presented the results of the TBP (Treatment Beyond Progression) trial, in which women who had progressed while on a trastuzumab-based regimen were randomly assigned to treatment with capecitabine monotherapy or capecitabine plus trastuzumab.
Previous studies (A Diabetes Outcome Progression Trial, U.K. Prospective Diabetes Study [ 3, 4]) have clearly documented the progressive decline in β-cell function over time even in the presence of therapy, including sulfonylureas, metformin, and thiazolidinediones.
This issue has been recently dealt with in A Diabetes Outcome Progression Trial (ADOPT).
A Diabetes Outcome Progression Trial (ADOPT) evaluated the durability of several oral antidiabetes monotherapies over 5 years.
TZD's durability of effect was shown in the 3-year stable A1C data from A Diabetes Outcome Progression Trial (ADOPT).
ADOPT (A Diabetes Outcome Progression Trial) compared rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes.
Similar(17)
Progression from trial to trial was experimenter controlled with a mouse click, and 12 series of 2 to 5 serially presented trials were administered.
All patients had radiological evidence of progression at trial entry.
All the patients in our analysis had evidence of disease progression before trial entry.
Rheumatologists frequently question whether the small differences in radiographic progression between trial arms are clinically meaningful.
During gefitinib monotherapy, physical examination, haematology, biochemistry, evaluation of adverse events and radiographic tumour assessment were performed every 6 weeks until patient progression or trial closure.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com